Equities Analysts Issue Forecasts for TARA Q2 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Protara Therapeutics in a research note issued on Monday, November 24th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.36) EPS.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Monday, November 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.60.

Protara Therapeutics Price Performance

Shares of TARA stock opened at $7.37 on Tuesday. The firm has a market cap of $284.39 million, a P/E ratio of -4.55 and a beta of 1.59. The firm has a fifty day moving average of $4.98 and a two-hundred day moving average of $3.79. Protara Therapeutics has a 1-year low of $2.36 and a 1-year high of $10.48.

Institutional Trading of Protara Therapeutics

Several large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. acquired a new position in Protara Therapeutics during the 1st quarter valued at $64,000. American Century Companies Inc. bought a new position in Protara Therapeutics in the first quarter valued at about $154,000. Walleye Capital LLC raised its position in shares of Protara Therapeutics by 3.9% during the 1st quarter. Walleye Capital LLC now owns 229,454 shares of the company’s stock valued at $977,000 after acquiring an additional 8,640 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Protara Therapeutics in the 1st quarter valued at approximately $320,000. Finally, Velan Capital Investment Management LP lifted its holdings in Protara Therapeutics by 5.6% during the first quarter. Velan Capital Investment Management LP now owns 1,667,800 shares of the company’s stock worth $7,105,000 after acquiring an additional 88,800 shares in the last quarter. Institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.